SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 2021 Biotech Stock Picking Charity Contest
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: technetium who wrote (139)4/23/2021 12:29:53 PM
From: JFMWinter  Read Replies (1) of 307
 
$sppi PRed in March that their South Korean plant inspection is scheduled for May (they were notified of the delay by the FDA in Oct 2020). So there must still be quite a backlog.

Other factors that may or may not influence when $rvnc gets inspected:

I am not sure, but I think the $sppi drug is for cancer. As you pointed out the FDA may prioritize COVID, cancer etc over botox

"In December, Revance also entered into an amended supply agreement with Ajinomoto Bio-Pharma Services for the supply of DaxibotulinumtoxinA for Injection, which will complement its Northern California-based manufacturing location with a second Southern California-based location."


So possible both plants have to be inspected (instead of one now and one later)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News